BR0212470A - Métodos para produção de um ingrediente ativo de uma droga ou agente diagnóstico em cultura em suspensão de células mdck - Google Patents

Métodos para produção de um ingrediente ativo de uma droga ou agente diagnóstico em cultura em suspensão de células mdck

Info

Publication number
BR0212470A
BR0212470A BR0212470-0A BR0212470A BR0212470A BR 0212470 A BR0212470 A BR 0212470A BR 0212470 A BR0212470 A BR 0212470A BR 0212470 A BR0212470 A BR 0212470A
Authority
BR
Brazil
Prior art keywords
drug
producing
active ingredient
diagnostic agent
methods
Prior art date
Application number
BR0212470-0A
Other languages
English (en)
Inventor
Juergen Vorlop
Christian Frech
Holger Luebben
Jens-Peter Gregersen
Original Assignee
Chiron Behring Gmbh & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Behring Gmbh & Co filed Critical Chiron Behring Gmbh & Co
Publication of BR0212470A publication Critical patent/BR0212470A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16651—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16751—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18551—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

"MéTODOS PARA PRODUçãO DE UM INGREDIENTE ATIVO DE UMA DROGA OU AGENTE DIAGNóSTICO EM CULTURA EM SUSPENSãO DE CéLULAS MDCK". A presente invenção está relacionada a um método para produção de um ingrediente ativo de uma droga ou agente diagnóstico, no qual (a) células MDCK são infectadas com um vírus; e (b) células MDCK são cultivadas em cultura em suspensão em uma escala comercial sob condições que permitem a multiplicação dos vírus; nas quais o cultivo ocorre em um volume de pelo menos 30 l. A invenção também está relacionada a um método para produção de uma droga ou agente diagnóstico no qual um ingrediente ativo é produzido de acordo com o método acima e misturado com um adjuvante adequado, auxiliar, tampão, diluente ou transportador de droga.
BR0212470-0A 2001-09-12 2002-09-11 Métodos para produção de um ingrediente ativo de uma droga ou agente diagnóstico em cultura em suspensão de células mdck BR0212470A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10144906A DE10144906B4 (de) 2001-09-12 2001-09-12 Verfahren zur großtechnischen Herstellung von Impfstoffen
PCT/EP2002/010208 WO2003023021A2 (de) 2001-09-12 2002-09-11 Verfahren zur herstellung eines aktiven bestandteils eines arznei- oder diagnosemittels in mdck-zell-suspensionskultur

Publications (1)

Publication Number Publication Date
BR0212470A true BR0212470A (pt) 2004-08-24

Family

ID=7698764

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0212470-0A BR0212470A (pt) 2001-09-12 2002-09-11 Métodos para produção de um ingrediente ativo de uma droga ou agente diagnóstico em cultura em suspensão de células mdck

Country Status (17)

Country Link
US (1) US10329536B2 (pt)
EP (3) EP2011862B1 (pt)
JP (4) JP2005532779A (pt)
KR (1) KR100999345B1 (pt)
AT (2) ATE479742T1 (pt)
AU (2) AU2002338667B2 (pt)
BR (1) BR0212470A (pt)
CA (1) CA2455189C (pt)
CY (2) CY1110964T1 (pt)
DE (3) DE10144906B4 (pt)
DK (2) DK1427815T3 (pt)
ES (2) ES2351300T3 (pt)
HK (1) HK1062030A1 (pt)
NZ (1) NZ532202A (pt)
PT (2) PT2011862E (pt)
SI (1) SI1427815T1 (pt)
WO (1) WO2003023021A2 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1747268A1 (en) * 2004-05-20 2007-01-31 ID Biomedical Corporation Process for the production of an influenza vaccine
DK2578229T3 (da) 2004-09-09 2013-10-07 Novartis Vaccines & Diagnostic Faldende potentielle iatrogene risici associeret med vaccine-antigener
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
NZ567817A (en) 2005-11-01 2012-01-12 Novartis Vaccines & Diagnostic Cell-derived viral vaccines with low levels of residual cell DNA by beta-propiolactone treatment
EP1951301A2 (en) 2005-11-04 2008-08-06 Novartis Vaccines and Diagnostics S.r.l. Emulsions with free aqueous-phase surfactant for adjuvanting split influenza vaccines
EP1951302A2 (en) 2005-11-04 2008-08-06 Novartis Vaccines and Diagnostics S.r.l. Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
EP1951299B1 (en) 2005-11-04 2012-01-04 Novartis Vaccines and Diagnostics S.r.l. Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
PL1945252T3 (pl) 2005-11-04 2013-11-29 Seqirus Uk Ltd Szczepionki zawierające oczyszczone antygeny powierzchniowe otrzymane z wirusów grypy hodowanych w hodowli komórkowej i skwalen jako adiuwant
CN102755645A (zh) 2005-11-04 2012-10-31 诺华疫苗和诊断有限公司 佐剂配制的包含细胞因子诱导剂的流感疫苗
US20100068223A1 (en) 2006-03-24 2010-03-18 Hanno Scheffczik Storage of Influenza Vaccines Without Refrigeration
JP2009532352A (ja) 2006-03-31 2009-09-10 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ワクチンのための高力価組み換えインフルエンザ・ウィルス
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
KR20090057015A (ko) 2006-09-11 2009-06-03 노파르티스 아게 난을 사용하지 않는 인플루엔자 바이러스 백신의 제조
BRPI0716724A2 (pt) 2006-09-15 2013-10-01 Medimmune Llc cÉlula renal canina de madin-darby, e, mÉtodos para proliferar a mesma, para produzir vÍrus da influenza adaptados ao frio e apra eliminar contaminantes de dna de uma preparaÇço viral
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
EP2484377A1 (en) 2007-06-27 2012-08-08 Novartis AG Low-additive influenza vaccines
US9439960B2 (en) * 2007-10-10 2016-09-13 The Trustees Of Princeton University Cytomegalovirus vaccines and methods of production
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
EP2334328A4 (en) 2008-09-24 2012-08-29 Medimmune Llc METHOD FOR CLEANING VIRUSES
KR20120027276A (ko) 2009-04-27 2012-03-21 노파르티스 아게 인플루엔자를 예방하기 위한 면역증강된 백신
EP2456855B1 (en) * 2009-07-23 2017-03-29 GE Healthcare Bio-Sciences Corp. Drain down and re-feed of microcarrier bioreactor
WO2011056591A1 (en) 2009-10-26 2011-05-12 Warf - Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in vero cells
US20110142863A1 (en) 2009-12-16 2011-06-16 Millipore Corporation Flow through purification processes for large biomolecules
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
EP2566958B1 (en) * 2010-05-03 2015-12-30 GlaxoSmithKline Biologicals S.A. Method for inactivating influenza virus
US9426989B2 (en) 2010-05-06 2016-08-30 Novartis Ag Organic peroxide compounds for microorganism inactivation
US8945904B2 (en) 2010-05-21 2015-02-03 Novartis Ag Influenza virus reassortment
JP5976639B2 (ja) 2010-06-01 2016-08-23 ノバルティス アーゲー インフルエンザワクチン抗原の濃縮および凍結乾燥
CA2801149A1 (en) 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens without lyophilization
ES2531577T3 (es) 2010-08-20 2015-03-17 Novartis Ag Conjuntos de agujas para la administración de vacuna soluble contra la gripe
WO2012033236A1 (ko) 2010-09-06 2012-03-15 에스케이케미칼 주식회사 무혈청 배양 및 부유 배양에 적응된 ｍｄｃｋ 세포주 및 상기 세포를 사용하여 백신용 바이러스를 제조하는 방법
WO2012082723A2 (en) 2010-12-15 2012-06-21 Emd Millipore Corporation Purification of immunogens using a non-polysaccharide matrix
GB201216121D0 (en) 2012-09-10 2012-10-24 Novartis Ag Sample quantification by disc centrifugation
CN104159608A (zh) 2012-03-06 2014-11-19 克鲁塞尔荷兰公司 针对流感的改善的疫苗接种
KR101370512B1 (ko) * 2013-06-07 2014-03-06 재단법인 목암생명공학연구소 무단백 배지에서 부유 배양되는 mdck 유래 세포주 및 상기 세포주를 이용하여 바이러스를 증식시키는 방법
US9950057B2 (en) 2013-07-15 2018-04-24 Wisconsin Alumni Research Foundation (Warf) High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
US11013795B2 (en) 2015-06-26 2021-05-25 Seqirus UK Limited Antigenically matched influenza vaccines
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
AU2016290603B2 (en) 2015-07-07 2022-06-02 Seqirus UK Limited Influenza potency assays
US10786564B2 (en) * 2015-10-30 2020-09-29 National Health Research Institutes MDCK suspension cell lines in serum-free, chemically-defined media for vaccine production
CN105561317B (zh) * 2015-12-22 2018-03-20 肇庆大华农生物药品有限公司 重组伪狂犬病病毒疫苗耐热冻干保护剂及其制备方法
WO2017143236A1 (en) 2016-02-19 2017-08-24 Yoshihiro Kawaoka Improved influenza b virus replication for vaccine development
EP3914295A2 (en) 2019-01-23 2021-12-01 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
WO2020163804A1 (en) 2019-02-08 2020-08-13 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
CN114929269A (zh) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
CN110237246B (zh) * 2019-07-25 2022-11-15 北京鼎持生物技术有限公司 一种全悬浮细胞培养禽流感（h9）灭活疫苗的方法
JP2022551805A (ja) 2019-08-27 2022-12-14 ウィスコンシン アルムニ リサーチ ファンデイション 卵内複製のための安定化されたｈａを持つ組換えインフルエンザウイルス
EP4061930A1 (en) 2019-11-18 2022-09-28 Seqirus Pty Ltd Method for producing reassortant influenza viruses
AU2021297631A1 (en) * 2020-06-22 2023-02-02 Kolon Life Science, Inc. Method for mass-producing vaccinia virus by using suspension cells

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1278075B (de) 1964-06-22 1968-09-19 Norden Lab Inc Verwendung von Gewebekulturen zur Zuechtung von Viren fuer die Gewinnung von Impfstoffen
US4064232A (en) * 1974-01-14 1977-12-20 Sandoz Ltd. Process for isolating the immunogenic components of influenza viruses
CA1122527A (en) * 1979-05-15 1982-04-27 Karen K. Brown Influenza vaccine production in liquid cell culture
US4500513A (en) * 1979-05-15 1985-02-19 Miles Laboratories, Inc. Influenza vaccine production in liquid cell culture
USRE33164E (en) * 1979-05-15 1990-02-13 Mobay Corporation Influenza vaccine production in liquid cell culture
US4525349A (en) 1981-12-29 1985-06-25 Societe Anonyme Dite: Institut Merueux Process for the large-scale production of a vaccine against poliomyelitis and the resulting vaccine
US5013663A (en) * 1983-06-15 1991-05-07 American Home Products Corporation Canine corona virus vaccine
US4783411A (en) * 1984-10-22 1988-11-08 Janis Gabliks Influenza-A virus vaccine from fish cell cultures
ES2081864T3 (es) 1989-03-29 1996-03-16 Univ New York State Res Found Metodo para purificar una proteina de la membrana exterior de haemophilus influenzae.
AT393277B (de) 1990-01-04 1991-09-25 Immuno Ag Verfahren zur herstellung von fruehsommer- meningoenzephalitis-virus (fsme-virus)-antigen
MY107664A (en) * 1991-01-17 1996-05-30 Kao Corp Novel alkaline proteinase and process for producing the same
GB9110808D0 (en) * 1991-05-17 1991-07-10 Retroscreen Ltd Aids vaccine and method for its production
WO1993022448A1 (en) * 1992-05-01 1993-11-11 Teijin Limited Fed batch culture method for protein secreting cells
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
US5824536A (en) 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
US5753489A (en) * 1994-11-10 1998-05-19 Immuno Ag Method for producing viruses and vaccines in serum-free culture
ATE429246T1 (de) 1994-11-10 2009-05-15 Baxter Healthcare Sa Verfahren zur herstellung von biologischen produkten in protein-freiem kultur
US5756341A (en) * 1994-11-10 1998-05-26 Immuno Ag Method for controlling the infectivity of viruses
EP0808361A4 (en) 1994-11-16 2001-07-18 St Jude Childrens Res Hospital NEW REPLICATION PROCESS
US5646033A (en) * 1994-11-30 1997-07-08 Dyncorp African green monkey kidney cell lines useful for maintaining viruses and for preparation of viral vaccines
WO1997011093A2 (en) 1995-09-22 1997-03-27 Connaught Laboratories Limited Parainfluenza virus glycoproteins and vaccines
DE19612966B4 (de) * 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
DE19612967A1 (de) * 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
AU743546B2 (en) * 1998-10-05 2002-01-31 Research Foundation For Microbial Diseases Of Osaka University, The Enhanced immunogen for inactivated vaccine for infection with Japanese encephalitis viruses and process for producing the same
US6514502B1 (en) * 1999-01-26 2003-02-04 Schering-Plough Veterinary Corporation Propagation of bovine cononavirus in chinese hamster ovary cells
AU7950400A (en) * 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
WO2001064846A1 (en) * 2000-03-03 2001-09-07 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
AU2003246411A1 (en) 2002-06-11 2003-12-22 Glaxo Group Limited Immunogenic compositions
US20040223976A1 (en) 2003-03-07 2004-11-11 Elisabetta Bianchi Influenza virus vaccine
WO2004084938A1 (en) 2003-03-24 2004-10-07 Intercell Ag Improved vaccines
AR053833A1 (es) 2005-03-23 2007-05-23 Glaxosmithkline Biolog Sa Composicion inmunogenetica
KR20090057015A (ko) 2006-09-11 2009-06-03 노파르티스 아게 난을 사용하지 않는 인플루엔자 바이러스 백신의 제조
CN101522218B (zh) 2006-10-12 2012-09-26 葛兰素史密丝克莱恩生物有限公司 包含水包油乳液佐剂的疫苗
CN101553252A (zh) 2006-12-06 2009-10-07 诺华有限公司 包含来自于四株流感病毒的抗原的疫苗
TW200908994A (en) 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
US8506966B2 (en) 2008-02-22 2013-08-13 Novartis Ag Adjuvanted influenza vaccines for pediatric use
JP2013521771A (ja) 2010-03-08 2013-06-13 ノバルティス アーゲー 細胞内病原体について試験する方法

Also Published As

Publication number Publication date
CA2455189A1 (en) 2003-03-20
SI1427815T1 (sl) 2010-12-31
WO2003023021A2 (de) 2003-03-20
DE10144906B4 (de) 2013-11-28
PT1427815E (pt) 2010-12-07
KR20050027165A (ko) 2005-03-17
US10329536B2 (en) 2019-06-25
JP2010138205A (ja) 2010-06-24
DK1427815T3 (da) 2010-12-06
AU2008207588B2 (en) 2012-01-19
CY1113241T1 (el) 2016-04-13
AU2002338667B2 (en) 2008-10-02
JP5264812B2 (ja) 2013-08-14
HK1062030A1 (en) 2004-10-15
EP2216400A1 (de) 2010-08-11
EP2011862B1 (de) 2011-06-08
WO2003023021A3 (de) 2003-11-06
JP2011212021A (ja) 2011-10-27
ES2367833T3 (es) 2011-11-08
US20050118140A1 (en) 2005-06-02
NZ532202A (en) 2006-08-31
DE10144906A1 (de) 2003-03-27
JP2008289499A (ja) 2008-12-04
EP1427815B1 (de) 2010-09-01
JP2005532779A (ja) 2005-11-04
CA2455189C (en) 2012-01-10
ATE512213T1 (de) 2011-06-15
EP2011862A1 (de) 2009-01-07
KR100999345B1 (ko) 2010-12-09
ATE479742T1 (de) 2010-09-15
DK2011862T3 (da) 2011-09-12
AU2008207588A1 (en) 2008-09-18
DE122011000005I1 (de) 2011-06-16
CY1110964T1 (el) 2015-06-11
PT2011862E (pt) 2011-09-16
ES2351300T3 (es) 2011-02-02
EP1427815A2 (de) 2004-06-16
DE50214630D1 (de) 2010-10-14

Similar Documents

Publication Publication Date Title
BR0212470A (pt) Métodos para produção de um ingrediente ativo de uma droga ou agente diagnóstico em cultura em suspensão de células mdck
DE50214416D1 (de) Vermehrung von viren in zellkultur
BR9610550A (pt) Método para a produção de uma vacina viral para um vírus animal método para determinar a atividade de um composto contra um vírus animal e método para detectar a presença de um vírus em uma amostra
BR0207775A (pt) Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
AU9058091A (en) Preparation of nucleic acid samples
ATE482267T1 (de) Tierzellen und verfahren für die replikation von influenza viren
MY134424A (en) Stable influenza virus preparations with low or no amount of thiomersal
DK0891420T4 (da) Fremgangsmåde til replikation af influenzavirus i cellekultur samt de ved fremgangsmåden opnåelige influenzavirus
ATE322163T1 (de) Substituierte cyclopentanderivate die als neuramidase-inhibitoren nuetzlich sind
DK66692D0 (da) En mammal cytokin, il-11
FI971998A (fi) Menetelmä biologisten tuotteiden tuottamiseksi proteiinittomassa viljelmässä
BRPI0407636A (pt) meio de cultura de células, linhagem de células animais, métodos para produzir um meio de cultura condicionado, células animais, uma cultura de células animais, vìrus em uma cultura de células animais, ou, de preferência, humanas diplóides dependentes de ancoragem, método para produzir uma vacina, e, população de vìrus
DK1448229T3 (da) Farmaceutisk sammensætning til at inducere et immunrespons hos et menneske eller et dyr
FR2718963B1 (fr) Nouvelle composition pharmaceutique à base de taxoïdes.
DK208987D0 (da) Polypeptider og antistoffer, som er karakteristiske for papillomvirus, og deres anvendelse ved diagnostiske metoder og i vacciner
FI100111B (fi) Hyytymistekijää IX sisältävä kompleksi ja menetelmä sen valmistamiseks i
HUP0302600A2 (hu) Eljárás petefészektüszők in vitro tenyésztésére
ATE70453T1 (de) Verwendung von interleukin-1-proteinen gegen arthritis.
DE60213852D1 (de) Herstellung von zellsuspensionen
BR0311482A (pt) Agente de transformação bacteriana
OA09653A (en) Rubella peptides
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained
DK0852623T3 (da) Nukleinsyremolekyler kodende for proteiner, som medierer adhæsionen af Neisseria-celler til humane celler
DE60140526D1 (de) Herstellung von tcr gamma delta t-zellen
DK1163248T3 (da) 1,5-anhydro-D-fructose substitueret med en hydrofob gruppe til brug som en antioxidant og/eller emulgator

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: CHIRON BEHRING GMBH AND CO. KG (DE)

Free format text: NOME ALTERADO DE: CHIRON BEHRING GMBH AND CO.

B25D Requested change of name of applicant approved

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS GMBH AND CO. KG

Free format text: NOME ALTERADO DE: CHIRON BEHRING GMBH AND CO. KG

B25D Requested change of name of applicant approved

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS GMBH (DE)

Free format text: NOME ALTERADO DE: NOVARTIS VACCINES AND DIAGNOSTICS GMBH AND CO. KG

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: NOVARTIS AG (CH)

B15K Others concerning applications: alteration of classification

Ipc: C12N 7/00 (2006.01), A61K 39/00 (2006.01), A61P 31

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time